ESMO Congress 2021 - Proffered Paper session - Sarcoma

ESMO
9/21/21, 4:30 PM
Europe/Paris GMT+2

Description

LBA58 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer

Presentation Number

LBA58

Speakers

  • Florence Duffaud (Marseille, CEDEX 5, France)

Lecture Time

13:30 - 13:40

LBA59 - LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study

Presentation Number

LBA59

Speakers

  • Patricia Pautier (Villejuif, CEDEX, France)

Lecture Time

13:40 - 13:50

Invited Discussant LBA58 and LBA59

Speakers

  • Robin L. Jones (London, United Kingdom)

Lecture Time

13:50 - 14:00

Q&A and live discussion

Lecture Time

14:00 - 14:10

1520O - REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

Presentation Number

1520O

Speakers

  • Javier Martin Broto (Madrid, Spain)

Lecture Time

14:10 - 14:20

1521O - A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)

Presentation Number

1521O

Speakers

  • Yuki Kojima (Nagoya, Aichi, Japan)

Lecture Time

14:20 - 14:30

Invited Discussant 1520O and 1521O

Speakers

  • Sebastian Bauer (Essen, Germany)

Lecture Time

14:30 - 14:40

Q&A and live discussion

Lecture Time

14:40 - 14:50

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer, LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study, REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial, A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004), Q&A and live discussion

Inglês

 

Speakers

Florence Duffaud, Patricia Pautier, Robin L. Jones, Javier Martin Broto, Yuki Kojima, Sebastian Bauer

 

Link to the Event

Banner to the Event

ESMO Congress 2021 - Proffered Paper session - Sarcoma